市場調査レポート
商品コード
1427986

放射性医薬品セラノスティクスの世界市場レポート2024

Radiopharmaceutical Theranostics Global Market Report 2024

出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.89円
放射性医薬品セラノスティクスの世界市場レポート2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 目次
概要

放射性医薬品セラノスティクスの市場規模は、今後数年間で急速に成長すると予想されています。 2028年には14.4%の年間複合成長率(CAGR)で49億米ドルに成長すると予想されます。予測期間中に予想される成長は、バイオマーカーの発見と検証、ゲノムおよびプロテオミクス技術の進歩、高精度放射線治療の開発、学際的な協力、患者擁護とサポートの増加に起因すると考えられます。予測期間中に予想される顕著な動向には、倫理と合法性、遠隔医療のセラノスティクスへの統合、患者中心のケアへの移行、放射性医薬品のカスタマイズ、ナノセラノスティクスの開発に関連する考慮事項が含まれます。

放射性医薬品セラノスティクス市場は、がんの発生率の増加により成長する準備ができています。がんは、侵入して広がる可能性のある異常な細胞増殖を特徴とし、効果的な治療のためには標的を絞った個別のアプローチが必要です。 放射性医薬品セラノスティクスはがん治療において重要な役割を果たし、正確で個別化されたソリューションを提供します。米国単独でも、米国がん協会は、2023年に190万人が新たにがんと診断され、約609,820人が死亡する可能性があると推定しています。これらの診断の大部分(88%)は50歳以上の人々に発生すると予想されます。がんの罹患率の上昇は、放射性医薬品セラノスティクス市場の拡大を促進する重要な要因です。

放射性医薬品セラノスティクス市場の成長は、ヘルスケア費の増加によってさらに加速されます。 放射性医薬品セラノスティクス分野における政府の取り組み、助成金、研究開発資金によるサポートにより、イノベーションと新製品の開発が促進されます。 2023年6月のメディケア・メディケイド・サービスセンター(CMS)のデータによると、米国の国民医療支出は2021年に4兆3,000億米ドルに達し、国内総生産(GDP)の18.3%に寄与しました。この多額のヘルスケア費は、放射性医薬品セラノスティクス市場を牽引すると予想されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年~2023年
  • 世界の市場規模予測と成長、2023年~2028年、2033年

第6章 市場セグメンテーション

  • 世界の放射性医薬品セラノスティクス市場、製品タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • アルファエミッター
  • ベータエミッター
  • 陽電子放射断層撮影法(PET)トレーサー
  • 世界の放射性医薬品セラノスティクス市場、由来別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 原子炉
  • サイクロトロン
  • 世界の放射性医薬品セラノスティクス市場、放射性同位元素別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • テクネチウム99
  • ガリウム68
  • ヨウ素131
  • ヨウ素123
  • 18F
  • Y-90
  • ルテチウム(Lu)177
  • 銅(Cu)67
  • 銅(Cu)64
  • その他の放射線鏡
  • 世界の放射性医薬品セラノスティクス市場、適応症別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • オンコロジー
  • 心臓病学
  • 神経内科
  • その他の適応症
  • 世界の放射性医薬品セラノスティクス市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院
  • 画像診断センター
  • 学術調査機関
  • その他のエンドユーザー

第7章 地域および国の分析

  • 世界の放射性医薬品セラノスティクス市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界の放射性医薬品セラノスティクス市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 放射性医薬品セラノスティクス市場の競合情勢
  • 放射性医薬品セラノスティクス市場の企業プロファイル
    • Cardinal Health Inc.
    • AstraZeneca Plc
    • GE HealthCare Technologies Inc.
    • Bayer AG
    • China Grand Pharmaceutical &Healthcare.

第31章 その他の大手および革新的な企業

  • Lantheus Medical Imaging Inc.
  • Curium Pharma
  • Advanced Accelerator Applications
  • Telix Pharmaceuticals Ltd.
  • Bracco Imaging SpA
  • NTP Radioisotopes SOC Ltd.
  • Navidea Biopharmaceuticals Inc.
  • Jubilant DraxImage Inc.
  • NorthStar Medical Radioisotopes LLC
  • Blue Earth Diagnostics Ltd.
  • Precirix NV
  • SpectronRx
  • Viewpoint Molecular Targeting Inc.
  • NuView Life Sciences
  • Alpha-9 Theranostics Inc.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r13830

Radiopharmaceutical theranostics involves a combined medical approach that integrates therapeutics (treatment) and diagnostics (diagnosis) through the utilization of radiopharmaceuticals. These substances are employed for patient diagnosis, therapy, and personalized management.

The primary product categories within radiopharmaceutical theranostics include alpha emitters, beta emitters, and positron emission tomography (PET) tracers. Alpha emitters are radioactive substances emitting alpha particles, characterized by high-energy particles consisting of two protons and two neutrons. Various sources for these include nuclear reactors and cyclotrons, and the diverse radioisotopes encompass technetium-99, gallium-68, iodine-131, iodine-123, 18F, Y-90, lutetium (Lu) 177, copper (Cu) 67, copper (Cu) 64, among others. These radiopharmaceuticals find applications in oncology, cardiology, neurology, and other medical indications, and are utilized by various end-users, including hospitals, diagnostic imaging centers, academic and research institutes, and others.

The radiopharmaceutical theranostics market research report is one of a series of new reports from The Business Research Company that provides radiopharmaceutical theranostics market statistics, including radiopharmaceutical theranostics industry global market size, regional shares, competitors with a radiopharmaceutical theranostics market share, detailed radiopharmaceutical theranostics market segments, market trends, and opportunities, and any further data you may need to thrive in the radiopharmaceutical theranostics industry. This radiopharmaceutical theranostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The radiopharmaceutical theranostics market size has grown rapidly in recent years. It will grow from $2.51 billion in 2023 to $2.86 billion in 2024 at a compound annual growth rate (CAGR) of 14.1%. The increase observed in the historical period can be attributed to the development of radiopharmaceuticals, advances in clinical research, investments in research, regulatory approvals, and progress in nuclear medicine.

The radiopharmaceutical theranostics market size is expected to see rapid growth in the next few years. It will grow to $4.9 billion in 2028 at a compound annual growth rate (CAGR) of 14.4%. The anticipated growth in the forecast period can be attributed to the discovery and validation of biomarkers, advancements in genomic and proteomic technologies, the development of precision radiotherapy, interdisciplinary collaborations, and increased patient advocacy and support. Prominent trends expected during the forecast period include considerations related to ethics and legality, the integration of telemedicine in theranostics, a shift towards patient-centric care, the customization of radiopharmaceuticals, and the development of nano-theranostics.

The radiopharmaceutical theranostics market is poised for growth, driven by the increasing incidence of cancer. Cancer, characterized by abnormal cell growth that can invade and spread, necessitates targeted and personalized approaches for effective treatment. Radiopharmaceutical theranostics plays a crucial role in cancer treatment, offering precision and personalized solutions. In the US alone, the American Cancer Society estimates that 1.9 million new cancer cases may be diagnosed in 2023, resulting in approximately 609,820 deaths. The majority of these diagnoses, 88%, are expected to be in individuals aged 50 and above. The rising prevalence of cancer is a key factor fueling the expansion of the radiopharmaceutical theranostics market.

The growth of the radiopharmaceutical theranostics market is further augmented by the increasing healthcare expenditure. Support from government initiatives, grants, and R&D funding in the radiopharmaceutical theranostics field encourages innovation and the development of new products. According to data from the Centers for Medicare & Medicaid Services (CMS) in June 2023, the national health expenditure in the US reached $4.3 trillion in 2021, contributing to 18.3% of the Gross Domestic Product (GDP). This significant healthcare expenditure is expected to drive the radiopharmaceutical theranostics market.

A prominent trend in the radiopharmaceutical theranostics market is technological advancement. Major companies in the market are actively developing advanced technologies to maintain their competitive positions. In March 2021, GE HealthCare Technologies Inc. introduced StarGuide, its latest SPECT/CT technology designed to advance precision health and theranostics. The system incorporates Cadmium Zinc Telluride (CZT) technology, allowing healthcare providers to gain deeper insights into patient conditions and improve outcomes across various care areas. The digital focus detectors and 360-degree imaging of StarGuide are anticipated to enhance precision health and theranostics capabilities in nuclear medicine.

Companies operating in the radiopharmaceutical theranostics market are also focusing on the development of theranostics for cancer treatment. Theranostic approaches aim to provide targeted therapies and diagnostic solutions for rare diseases, particularly for patients with limited treatment options such as cancer. In November 2023, GE HealthCare Technologies Inc. launched theranostic solutions for cancer, marking a significant stride in precision medicine. Theranostics utilizes therapeutic agents in conjunction with imaging technology to identify and target cancer cells for destruction.

In March 2023, Radiopharm Theranostics, an Australia-based biotechnology company, acquired Pharma15 Corporation for $4 million. This strategic move positions Radiopharm to explore next-generation radiopharmaceuticals for prostate cancer treatment, surpassing PSMA-based therapies, and advancing innovative solutions for patients. Pharma15 Corporation, a US-based pharmaceutical company, specializes in radio-immuno-theranostics platforms and pharmaceutical products' development, aligning with Radiopharm's focus on advancing radiopharmaceutical products.

Major companies operating in the radiopharmaceutical theranostics market report are Cardinal Health Inc., AstraZeneca PLC, GE HealthCare Technologies Inc., Bayer AG, China Grand Pharmaceutical & Healthcare., Lantheus Medical Imaging Inc., Curium Pharma, Advanced Accelerator Applications, Telix Pharmaceuticals Ltd., Bracco Imaging S.p.A, NTP Radioisotopes SOC Ltd., Navidea Biopharmaceuticals Inc., Jubilant DraxImage Inc., NorthStar Medical Radioisotopes LLC, Blue Earth Diagnostics Ltd., Precirix NV, SpectronRx, Viewpoint Molecular Targeting Inc., NuView Life Sciences, Alpha-9 Theranostics Inc., RadioMedix Inc., RayzeBio Inc., Fusion Pharmaceuticals Inc., Actinium Pharmaceuticals Inc., Eckert & Ziegler Strahlen- und Medizintechnik AG, Ariceum Therapeutics GmbH, Radiopharm Theranostics Ltd., Ratio Therapeutics Inc., Primo Biotechnology, Bivision Biomedical Technology (Nanjing) Co. Ltd.

North America was the largest region in the radiopharmaceutical theranostics market in 2023. The regions covered in the radiopharmaceutical theranostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the radiopharmaceutical theranostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The radiopharmaceutical theranostics market includes revenues earned by providing genetic testing, targeted therapy services, contract development, and manufacturing services, consultation and interpretation, and personalized therapeutic interventions. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Radiopharmaceutical Theranostics Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on radiopharmaceutical theranostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for radiopharmaceutical theranostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The radiopharmaceutical theranostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Product Type: Alpha Emitters; Beta Emitters; Positron Emission Tomography (PET) Tracers
  • 2) By Source: Nuclear Reactors; Cyclotrons
  • 3) By Radioisotope: Technetium-99; Gallium-68; Iodine-131; Iodine-123; 18F; Y-90; Lutetium (Lu) 177; Copper (Cu) 67; Copper (Cu) 64; Other Radioscopes
  • 4) By Indication: Oncology; Cardiology; Neurology; Other Indications
  • 5) By End User: Hospitals; Diagnostic Imaging Centers; Academic And Research Institutes; Other End Users
  • Companies Mentioned: Cardinal Health Inc.; AstraZeneca Plc; GE HealthCare Technologies Inc.; Bayer AG; China Grand Pharmaceutical & Healthcare.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Radiopharmaceutical Theranostics Market Characteristics

3. Radiopharmaceutical Theranostics Market Trends And Strategies

4. Radiopharmaceutical Theranostics Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Radiopharmaceutical Theranostics Market Size and Growth

  • 5.1. Global Radiopharmaceutical Theranostics Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Radiopharmaceutical Theranostics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Radiopharmaceutical Theranostics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Radiopharmaceutical Theranostics Market Segmentation

  • 6.1. Global Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Alpha Emitters
  • Beta Emitters
  • Positron Emission Tomography (PET) Tracers
  • 6.2. Global Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Nuclear Reactors
  • Cyclotrons
  • 6.3. Global Radiopharmaceutical Theranostics Market, Segmentation By Radioisotope, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Technetium-99
  • Gallium-68
  • Iodine-131
  • Iodine-123
  • 18F
  • Y-90
  • Lutetium (Lu) 177
  • Copper (Cu) 67
  • Copper (Cu) 64
  • Other Radioscopes
  • 6.4. Global Radiopharmaceutical Theranostics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oncology
  • Cardiology
  • Neurology
  • Other Indications
  • 6.5. Global Radiopharmaceutical Theranostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Diagnostic Imaging Centers
  • Academic And Research Institutes
  • Other End Users

7. Radiopharmaceutical Theranostics Market Regional And Country Analysis

  • 7.1. Global Radiopharmaceutical Theranostics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Radiopharmaceutical Theranostics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Radiopharmaceutical Theranostics Market

  • 8.1. Asia-Pacific Radiopharmaceutical Theranostics Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Radiopharmaceutical Theranostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Radiopharmaceutical Theranostics Market

  • 9.1. China Radiopharmaceutical Theranostics Market Overview
  • 9.2. China Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Radiopharmaceutical Theranostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Radiopharmaceutical Theranostics Market

  • 10.1. India Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Radiopharmaceutical Theranostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Radiopharmaceutical Theranostics Market

  • 11.1. Japan Radiopharmaceutical Theranostics Market Overview
  • 11.2. Japan Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Radiopharmaceutical Theranostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Radiopharmaceutical Theranostics Market

  • 12.1. Australia Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Radiopharmaceutical Theranostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Radiopharmaceutical Theranostics Market

  • 13.1. Indonesia Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Radiopharmaceutical Theranostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Radiopharmaceutical Theranostics Market

  • 14.1. South Korea Radiopharmaceutical Theranostics Market Overview
  • 14.2. South Korea Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Radiopharmaceutical Theranostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Radiopharmaceutical Theranostics Market

  • 15.1. Western Europe Radiopharmaceutical Theranostics Market Overview
  • 15.2. Western Europe Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Radiopharmaceutical Theranostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Radiopharmaceutical Theranostics Market

  • 16.1. UK Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Radiopharmaceutical Theranostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Radiopharmaceutical Theranostics Market

  • 17.1. Germany Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Radiopharmaceutical Theranostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Radiopharmaceutical Theranostics Market

  • 18.1. France Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Radiopharmaceutical Theranostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Radiopharmaceutical Theranostics Market

  • 19.1. Italy Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Radiopharmaceutical Theranostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Radiopharmaceutical Theranostics Market

  • 20.1. Spain Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Radiopharmaceutical Theranostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Radiopharmaceutical Theranostics Market

  • 21.1. Eastern Europe Radiopharmaceutical Theranostics Market Overview
  • 21.2. Eastern Europe Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Radiopharmaceutical Theranostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Radiopharmaceutical Theranostics Market

  • 22.1. Russia Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Radiopharmaceutical Theranostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Radiopharmaceutical Theranostics Market

  • 23.1. North America Radiopharmaceutical Theranostics Market Overview
  • 23.2. North America Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Radiopharmaceutical Theranostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Radiopharmaceutical Theranostics Market

  • 24.1. USA Radiopharmaceutical Theranostics Market Overview
  • 24.2. USA Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Radiopharmaceutical Theranostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Radiopharmaceutical Theranostics Market

  • 25.1. Canada Radiopharmaceutical Theranostics Market Overview
  • 25.2. Canada Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Radiopharmaceutical Theranostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Radiopharmaceutical Theranostics Market

  • 26.1. South America Radiopharmaceutical Theranostics Market Overview
  • 26.2. South America Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Radiopharmaceutical Theranostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Radiopharmaceutical Theranostics Market

  • 27.1. Brazil Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Radiopharmaceutical Theranostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Radiopharmaceutical Theranostics Market

  • 28.1. Middle East Radiopharmaceutical Theranostics Market Overview
  • 28.2. Middle East Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Radiopharmaceutical Theranostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Radiopharmaceutical Theranostics Market

  • 29.1. Africa Radiopharmaceutical Theranostics Market Overview
  • 29.2. Africa Radiopharmaceutical Theranostics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Radiopharmaceutical Theranostics Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Radiopharmaceutical Theranostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Radiopharmaceutical Theranostics Market Competitive Landscape And Company Profiles

  • 30.1. Radiopharmaceutical Theranostics Market Competitive Landscape
  • 30.2. Radiopharmaceutical Theranostics Market Company Profiles
    • 30.2.1. Cardinal Health Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. AstraZeneca Plc
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. GE HealthCare Technologies Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Bayer AG
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. China Grand Pharmaceutical & Healthcare.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Radiopharmaceutical Theranostics Market Other Major And Innovative Companies

  • 31.1. Lantheus Medical Imaging Inc.
  • 31.2. Curium Pharma
  • 31.3. Advanced Accelerator Applications
  • 31.4. Telix Pharmaceuticals Ltd.
  • 31.5. Bracco Imaging S.p.A
  • 31.6. NTP Radioisotopes SOC Ltd.
  • 31.7. Navidea Biopharmaceuticals Inc.
  • 31.8. Jubilant DraxImage Inc.
  • 31.9. NorthStar Medical Radioisotopes LLC
  • 31.10. Blue Earth Diagnostics Ltd.
  • 31.11. Precirix NV
  • 31.12. SpectronRx
  • 31.13. Viewpoint Molecular Targeting Inc.
  • 31.14. NuView Life Sciences
  • 31.15. Alpha-9 Theranostics Inc.

32. Global Radiopharmaceutical Theranostics Market Competitive Benchmarking

33. Global Radiopharmaceutical Theranostics Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Radiopharmaceutical Theranostics Market

35. Radiopharmaceutical Theranostics Market Future Outlook and Potential Analysis

  • 35.1 Radiopharmaceutical Theranostics Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Radiopharmaceutical Theranostics Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Radiopharmaceutical Theranostics Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer